IDT Australia Limited

Equities

IDT

AU000000IDT0

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 04:54:05 16/05/2024 BST			5-day change	1st Jan Change
0.099 ^AUD	-1.00%		+4.21%	-10.00%

05-06	IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility	MT
04-16	IDT Australia Signs Master Service Agreement with Sanofi	MT

IDT Australia Limited Appoints Jane Ryan as an Independent Non-Executive Director

January 28, 2022 at 01:42 am

IDT Australia Limited announced that Dr. Jane Ryan has been appointed as an independent non-executive Director, effective 28 January 2022. Dr. Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management.

Jane is currently a Non-Executive Director of Anatara Lifesciences Ltd. and Bionomics Ltd.

Latest news about IDT Australia Limited

IDT Australia Secures Victorian Government Funding for Cancer Medication Production Facility	05-06	MT
IDT Australia Signs Master Service Agreement with Sanofi	04-16	MT
IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-21	CI
Invion Nears Clinical Trial of Cancer Photodynamic Therapy with Drug Substance Production	11-21	MT
IDT Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
IDT Australia Raises AU$2 Million Via Share Purchase Plan	20/07/23	MT
IDT Australia Limited Provides Preliminary Unaudited Revenue Update for the Three Months to End June 2023	10/07/23	CI
IDT Australia to Open AU$2 Million Share Purchase Plan; Shares Rise 3%	21/06/23	MT
IDT Australia Completes First Tranche of AU$5 Million Placement	12/06/23	MT
IDT Australia Raises AU$5 Million for Capex Program; Shares Fall 28%	05/06/23	MT
IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023	27/04/23	CI
IDT Australia Achieves Expansion of License to Manufacture Advanced Therapies	28/03/23	MT
IDT Achieves Key Milestone with TGA License Upgrade	27/03/23	CI
IDT Australia Transitions Interim CEO to Permanent Role	02/03/23	MT
IDT Australia Limited Announces the Appointment of Paul McDonald as Chief Executive Officer	02/03/23	CI
IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
IDT Australia Chairman to Retire	21/12/22	MT
IDT Australia Limited Announces Board Changes	09/10/22	CI
IDT Australia Names Acting CFO	28/09/22	MT
IDT Australia Limited Announces Appointment of Mark Licciardo as Company Secretary	27/09/22	CI
IDT Australia Limited Announces Appointment of Mahendran Vasanthakumar as Acting CFO	27/09/22	CI
IDT Australia Limited Announces Executive Changes	14/09/22	CI
IDT Australia Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
MedAdvisor Names Finance Chief	25/07/22	MT
IDT Australia's CFO Resigns	21/07/22	MT

Chart IDT Australia Limited

Duration

Period

More charts

Company Profile

IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities can produce both API and FDF positioning it as a facility in the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IDT AUSTRALIA LIMITED	-10.00%	23.26M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs